Journal
ANNALS OF ONCOLOGY
Volume 25, Issue 9, Pages 1681-1690Publisher
ELSEVIER
DOI: 10.1093/annonc/mdu145
Keywords
ESMO; consensus; non-small-cell lung cancer; pathology; molecular testing; recommendations
Categories
Funding
- European Society for Medical Oncology central funds
Ask authors/readers for more resources
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available